TASE FY26 Q2 net profit climbs 81% to NIS 78.9 million; revenue rises 36% to NIS 185.4 million
Reuters2026/08/04 15:41- TASE posted Q2 2026 revenue of NIS 185.4 million, up 36% year over year, on higher Clearing House services and trading and clearing commissions.
- Net profit more than doubled to NIS 78.9 million; costs rose 10% to NIS 88.4 million.
- Adjusted EBITDA climbed 60% to NIS 114.5 million.
- Board greenlit a share buyback of up to NIS 150 million through Dec. 31, 2026.
- CEO Ittai Ben Zeev cited Friday trading as lifting foreign investors’ trading share to 41% from 12.5%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
